Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

This study has been completed.
Celgene Corporation
Information provided by:
University of Arkansas Identifier:
First received: June 2, 2004
Last updated: July 1, 2010
Last verified: July 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2007
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):